首页> 外文OA文献 >Adverse reactions in patients with B-cell lymphomas during combined treatment with rituximab: In vitro evaluation of rituximab hypersensitivity by basophil activation test.

【2h】

Adverse reactions in patients with B-cell lymphomas during combined treatment with rituximab: In vitro evaluation of rituximab hypersensitivity by basophil activation test.

机译：利妥昔单抗联合治疗期间B细胞淋巴瘤患者的不良反应：通过嗜碱性粒细胞活化试验体外评估利妥昔单抗超敏反应。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Piva E; Chieco-Bianchi F; Krajcar V; Aversa S; Plebani M;
展开▼
作者单位

展开▼
年度 2012
总页数
原文格式 PDF
正文语种 eng
中图分类

相似文献

外文文献
中文文献
专利

1. Adverse reactions in patients with B-cell lymphomas during combined treatment with rituximab: In vitro evaluation of rituximab hypersensitivity by basophil activation test? [J] . Elisa Piva, Fulvia Chieco-Bianchi, Valentino Krajcar, AMERICAN JOURNAL OF HEMATOLOGY . 2012,第11期

机译：利妥昔单抗联合治疗期间B细胞淋巴瘤患者的不良反应：嗜碱性粒细胞活化试验体外评估利妥昔单抗超敏反应？
2. Efficacy and safety analysis of rituximab combined with chemotherapy in the treatment of B-cell lymphoma patients complicated with hepatitis B virus infection [J] . Wang S., Zhang Z., Cai H., Indian journal of cancer. . 2016,第3期

机译：利妥昔单抗联合化疗治疗B细胞淋巴瘤患者乙型肝炎病毒感染的疗效和安全分析
3. Phase II study of the tetrahydropyranyl adriamycin-cyclophosphamide, vincristine, and prednisolone regimen combined with rituximab as first-line treatment for elderly patients with diffuse large B-cell lymphoma. [J] . Kasahara S, Hara T, Tsurumi H, Leukemia and lymphoma . 2011,第4期

机译：四氢吡喃基阿霉素-环磷酰胺，长春新碱和泼尼松龙方案与利妥昔单抗联合治疗老年弥漫性大B细胞淋巴瘤的一线治疗的II期研究。
4. Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma [C] . Bohua Li, Hao Wang, Yajun Guo, International conference of molecular simulations and applied informatics technologies . 2012

机译：具有抗利妥昔单抗的B细胞淋巴瘤的有效抗肿瘤活性的利妥昔单抗变体的表征
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Is there a relationship between the infusion-related reaction and effect of rituximab in the treatment of patients with diffuse large B-cell lymphoma? [O] . Sang-Gon Park 2019

机译：弥漫性大B细胞淋巴瘤患者的输注相关反应与利妥昔单抗的疗效之间是否存在关系？
7. Efficacy and Adverse Effects of Rituximab Combined with a TCOP Regimen in Patients with Untreated Diffuse Large B-cell Lymphoma and Follicular Lymphoma [O] . Takako TAKEDA-USUI, Bungo SAITO, Takashi MAEDA, 2009

机译：利妥昔单抗联合TCOP方案在未处理扩散大型B细胞淋巴瘤和滤泡淋巴瘤患者中联合TCOP方案的疗效和不良反应

Adverse reactions in patients with B-cell lymphomas during combined treatment with rituximab: In vitro evaluation of rituximab hypersensitivity by basophil activation test.

著录项

引文网络

相似文献

相关主题

期刊订阅